Valion Bio
VBIO
5 hedge funds and large institutions have $329K invested in Valion Bio in 2022 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 1 increasing their positions, reducing their positions, and 4 closing their positions.
0% more ownership
Funds ownership: 0% → 0% (+0%)
29% less funds holding
Funds holding: 7 → 5 (-2)
33% less capital invested
Capital invested by funds: $492K → $329K (-$163K)
50% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$235K |
| 2 |
TRCT
Tower Research Capital (TRC)
New York
|
+$6.54K |
| 3 |
BlackRock
New York
|
+$3.27K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
E
Ergoteles
New York
|
-$68K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$60K |
| 3 |
SSA
Schonfeld Strategic Advisors
New York
|
-$42K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$18K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Renaissance Technologies
New York
| $197K | +$235K | +72 | New |
|
|
KC
2
Kepos Capital
New York
| $97K | – | – | – |
|
|
3
BlackRock
New York
| $15K | +$3.27K | +1 | +20% |
|
4
Osaic Holdings
Scottsdale,
Arizona
| $14K | – | – | – |
|
|
TRCT
5
Tower Research Capital (TRC)
New York
| $5K | +$6.54K | +2 | New |
|
|
TFS
6
TrustCore Financial Services
Brentwood,
Tennessee
| $1K | – | – | – |
|
|
E
7
Ergoteles
New York
| – | -$68K | -10 | Closed |
|
|
8
Vanguard Group
Malvern,
Pennsylvania
| – | -$60K | -9 | Closed |
|
|
SSA
9
Schonfeld Strategic Advisors
New York
| – | -$42K | -6 | Closed |
|
|
10
UBS Group
Zurich,
Switzerland
| – | -$18K | -3 | Closed |
|
VBIO Hedge Fund Activity: Q1 2022 in Review
5 of the 6,341 institutional investors tracked by Wall St. Rank reported a position in Valion Bio (VBIO) for Q1 2022, worth a combined $329K — down 33% from $492K a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of VBIO and 2 opened new positions — a net loss of 2 holders — while 0 trimmed existing stakes and 1 added.
The largest buyer was Renaissance Technologies, opening a new position worth an estimated $235K. The largest seller was Ergoteles, exiting entirely with an estimated $68K sold.
- 5 institutional investors held Valion Bio (VBIO) as of Q1 2022, down from 7 in Q4 2021.
- Funds reported $329K of Valion Bio stock for Q1 2022, down 33% quarter-over-quarter.
- 2 funds opened new Valion Bio positions in Q1 2022 and 4 closed out, a net change of -2 holders.
- The largest Valion Bio buyer in Q1 2022 was Renaissance Technologies, an estimated $235K added.
- The largest Valion Bio seller in Q1 2022 was Ergoteles, an estimated $68K sold.
Based on aggregated 13F filings for Q1 2022.